Alnylam Pharmaceuticals Q3 Earnings Conference Call - ALNYLAM PHARMACEUTICALS INC

Explicit Guidance:

• FY2026 Product Revenue: Reiterating guidance of $4.2 billion to $4.5 billion; expects to land at the low end ($4.2 billion) due to slower-than-anticipated demand translation from field expansion.
• FY2026 Q4 Outlook: Anticipates headwinds from inventory normalization and pricing adjustments in the U.S. market; no material top-line contribution expected from recent field force expansion during the forecast period.
• FY2027 Revenue: No specific guidance provided for 2027 product revenue at the upcoming JPMorgan conference; guidance to be issued alongside Q4 and full-year 2026 results in mid-February to allow observation of the final 340B CMS rule impacts.
• FY2027 Launch Timing: No change to the expected launch of Nucreceran for ATTR-CM, maintaining a 2030 timeline subject to positive study results and regulatory approval.
• Pivotal Study Initiation: Planning to initiate a placebo-controlled pivotal study for Brazosaran in Huntington's disease in 2027, pending regulatory alignment.
• Pipeline Data Updates:
  • ALN6400 (Bleeding Disorders): Phase 1 healthy volunteer data expected at ASH annual meeting in December 2025.
  • ALN6400 (Hereditary Hemorrhagic Telangiectasia - HHT): Phase 2 data expected in February 2026.
  • ALN2232 (Obesity): Phase 1 data expected in February 2026.

Business-Segment Outlook:

• TTR Franchise (Amvutra): Despite 52% Q3 growth, underlying demand growth remains below expectations; 80% of prevalent ATTR-CM patients remain untreated (significant long-term opportunity). TRX share currently at 24% with only ~33% of prescribers experienced; goal is to drive share growth by deepening utilization among existing prescribers and expanding the base to include new writers.
• TTR Franchise (Nucreceran): Enrollment for Triton-CM expanded to 2,250 patients (+500) to address lower-than-expected event rates in the evolving disease landscape; study enriched for early-stage patients using NT-proBNP criteria to maximize treatment effect probability.
• Pipeline (Huntington's Disease): Interim Phase 1 data for Brazosaran showed 60–64% median reduction in CSF mutant huntingtin, with no dose-dependent safety signals or CNS inflammatory markers; confidence high enough to advance to pivotal trials.
• Commercial Execution: 2,000+ new unique prescribers have adopted Amvutra since launch; non-clinical barriers (prior authorization, site of care coordination) are expected to ease after initial experience; focus on converting engagement into patient starts.

Market and Competitive Outlook:

• Demand Trends: Q3 U.S. TTR revenue growth driven by an $81M increase in demand (up $100M QoQ including inventory); ATTR-CM prescriptions grew ~40% YoY; market fundamentals remain robust with sustained category growth.
• Pricing and Reimbursement:
  • UnitedHealth: Implemented more restrictive first-line Amvutra policy for Medicare Advantage effective October 1st; expected to cause delays for new patients but no impact on existing patients.
  • Net Price: Modest Q3 increase; one-time $10M gross-to-net adjustment in Q3; Q4 pricing expected to be a headwind.
• Market Share: NBRX (New-to-Brand) share stable at >30%; TRX share at 24%; aim to reach ~33% TRX share by 2030 in the US.
• Competitive Landscape: Amvutra positioned as foundational treatment; Nucreceran targeted to offer deeper knockdown (>95%) with twice-yearly dosing to extend leadership.

Macro / Industry Outlook:

• 340B Rule: CMS proposed rule change expected to be finalized imminently; potential effective date January 1, 2027. If finalized as proposed, could substantially reduce Medicare Part B reimbursement for 340B-discounted drugs.
• 340B Impact: Anticipated to create Q4 ordering volatility as health systems reassess procurement and site-of-care strategies; long-term impact on gross-to-net and volume TBD based on health system responses.
• Market Size: US treated ATTR-CM population projected to reach 75,000 patients by 2030.
• Site of Care: 99% of covered lives have access; ~90% of patients live within 10 miles of a treatment site; expanding third-party infusion clinics and home infusion capabilities.

Strategic Initiatives:

• Field Force Expansion: Expanded customer-facing teams to broaden prescriber base; increased reach and volume of HCP engagements currently underway, with translation to demand growth expected to be gradual.
• Patient Access Mitigation: Preparing options to mitigate 340B rule impact: (1) Contracting to offer discounts to 340B covered entities; (2) Supporting patients to access alternate sites of care (third-party infusion clinics/home).
• Pivotal Study Amendment: Increasing Triton-CM sample size by 500 patients (total 2,250) to ensure adequate statistical power under conservative event rate assumptions; no change to launch timeline.
• Alnylam 2030 Vision: Aspiration to become the leading science-driven, fully integrated global biopharmaceutical company; diversified multi-franchise business targeting beyond TTR (e.g., Huntington's, Obesity, Bleeding Disorders).
• Brazosaran Development: Advancing two parallel studies: ongoing Phase 1b open-label extension (6-month dosing) and a large placebo-controlled pivotal study (initiation planned 2027).

Risks and Headwinds to Outlook:

• Commercial Execution Risk: Lag in converting new prescriber engagement into patient starts; "trial begets preference" dynamic implies adoption takes time, particularly among community prescribers less experienced with the disease.
• Regulatory/Reimbursement Risk: Finalization of CMS 340B rule could alter procurement pathways, potentially impacting volume and net pricing; legal challenges from hospital groups may delay implementation or outcomes.
• Payer Policy Risk: Restrictive first-line policies (e.g., UnitedHealth MA) may delay new patient starts despite exceptions processes.
• Clinical Trial Risk: Triton-CM enrollment enriched for early patients to maximize effect; success depends on maintaining event rates despite secular trends of earlier diagnosis and better background care (e.g., SGLT2 inhibitors).
• Market Saturation: Only ~24% TRX share achieved despite significant growth; conversion to higher share depends on overcoming non-clinical barriers and deepening utilization.

Management Tone on the Future:

• Confidence: High conviction in the Amvutra clinical profile, Nucreceran potential, and Brazosaran data; confident in the long-term 2030 CAGR of >25% and ability to capture ~1/3 of US market by 2030.
• Satisfaction: Not satisfied with the current pace of demand growth relative to commercial investments; acknowledges the "time" required for adoption to translate into revenue.
• Urgency: Describes approach as having "laser-like focus and urgency"; committed to executing field expansion and overcoming barriers despite short-term headwinds.
• Hedges: Guidance for 2026 reflects a "prudent view" assuming no material top-line contribution from recent field expansion; 2027 guidance withheld to await clarity on 340B rule.

Miscellaneous:

• Financial Performance: Q3 2026 product revenues grew 52% YoY to $1.3 billion; TTR revenues grew 59% YoY to $1.15 billion.
• Cash Position: Ended Q3 with $3.6 billion in cash, cash equivalents, and marketable securities.
• Profitability: Recognized $1.9 billion non-cash income tax benefit from release of valuation allowance; GAAP net income was $2.2 billion.
• Cost Structure: Non-GAAP R&D expenses up 21% ($376M); Non-GAAP SG&A up 13% ($296M) due to commercial investments.
• Royalties: Increased royalty rates on Amvutra (linked to Sanofi) contributed to a 5% decrease in gross margin to 72% in Q3.